Table 2.
Relationship Between BRAF V600E Mutation and Tumor Recurrence in PTC of Various Subtype Variants
| Type of PTC |
BRAF Mutation |
Tumor Recurrence |
Person-Years of Follow-Up | Recurrence Rates |
Model One* |
Model Two† |
Model Three |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall |
BRAF V600E Positive |
BRAF V600E Negative |
BRAF V600E Positive |
BRAF V600E Negative |
P§ | |||||||||||||||
| No. | % | No. | % | No. | % | No. | % | Per 1,000 Person-Years | 95% CI | Per 1,000 Person-Years | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||
| All types | 1,017 of 2,099 | 48.5 | 338 of 2,099 | 16.1 | 213 of 1,017 | 20.9 | 125 of 1,082 | 11.6 | 9,266.1 | 47.71 | 41.72 to 54.57 | 26.03 | 21.85 to 31.02 | < .001 | 1.82 | 1.46 to 2.28 | 1.63 | 1.29 to 2.06 | 1.38 | 1.07 to 1.80 |
| CPTC | 813 of 1,448 | 56.1 | 247 of 1,448 | 17.1 | 168 of 813 | 20.7 | 79 of 635 | 12.4 | 6,822.2 | 44.92 | 38.62 to 52.26 | 25.63 | 20.56 to 31.95 | < .001 | 1.75 | 1.34 to 2.29 | 1.48 | 1.11 to 1.96 | 1.46 | 1.08 to 1.99 |
| FVPTC | 89 of 431 | 20.6 | 43 of 431 | 10.0 | 19 of 89 | 21.3 | 24 of 342 | 7.0 | 1,585.7 | 53.84 | 34.34 to 84.40 | 19.47 | 13.05 to 29.04 | < .001 | 2.76 | 1.51 to 5.06 | 4.02 | 1.95 to 8.28 | 3.20 | 1.46 to 7.02 |
Abbreviations: CPTC, conventional papillary thyroid cancer; FVPTC, follicular-variant papillary thyroid cancer; HR, hazard ratio; PTC, papillary thyroid cancer.
*
Model one was unadjusted.
†
Model two was adjusted for patient age and sex and stratified by medical center.
‡
Model three was additionally adjusted for tumor size, extrathyroidal invasion, lymph node metastasis, and multifocality (and PTC subtypes for all-types group).
§
P values from Poisson regression comparing BRAF mutation–positive and –negative groups.